Premium
Combination chemotherapy for hormone‐refractory prostate carcinoma
Author(s) -
Syed Samira
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11788
Subject(s) - medicine , toxicity , prostate carcinoma , chemotherapy , refractory (planetary science) , prostate , oncology , hormone , carcinoma , prostate cancer , cancer research , cancer , biology , astrobiology
Although there has been progress in the development of chemotherapy combinations with enhanced activity in patients with hormone‐refractory prostate carcinoma, the innate lack of selectivity to tumor cells with those combinations has resulted in diminishing returns and has approached the limits of acceptable toxicity. However, progress is being made, and several promising new therapies offer the dual hopes of maximizing efficacy with minimal toxicity to normal tissues.